<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00853593</url>
  </required_header>
  <id_info>
    <org_study_id>116</org_study_id>
    <nct_id>NCT00853593</nct_id>
  </id_info>
  <brief_title>Model 4396 Left Ventricular (LV) Lead Study</brief_title>
  <acronym>4396</acronym>
  <official_title>Model 4396 Left Ventricular Lead Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to show that a new lead, which paces the left bottom chamber (left
      ventricle) of the heart, is safe and effective. Using a lead on the left side of the heart
      has been shown to potentially improve heart failure symptoms. The shape and size of this new
      lead may make it a good choice for patients or physicians.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, multi-center, non-randomized design. All consented patients who
      meet all inclusion and no exclusion criteria may receive the investigational lead. The study
      design has statistical power to show safety at one-month after implant. It also has
      statistical power to show effectiveness at one-month and three-months after implant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (Subjects Without a Model 4396 Lead Related Complication)</measure>
    <time_frame>One month</time_frame>
    <description>A subject who was free of a Model 4396 lead related complication by the one month visit. All adverse events (AE) in the time frame were recorded at the subject's center and assessed by a centralized Adverse Event Advisory Committee (AEAC). The AEAC determined whether an AE was a complication and whether the event was related to the Model 4396 lead. A complication is an AE that results in death, termination of significant device function or invasive intervention (any therapy that penetrates the skin including administration of intramuscular (IM) and parenteral (IV) fluids).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Distal Tip Electrode Voltage Threshold</measure>
    <time_frame>One month</time_frame>
    <description>Subjects' distal tip electrode voltage threshold was collected at the one month visit. The Model 4396 was considered effective if the mean voltage threshold was less than 3.0 Volts. Voltage threshold was collected using LV tip to Right Ventricular (RV) coil configuration at 0.5 milliseconds [ms]. Voltage threshold is the minimum energy required from the device to consistently pace the ventricle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Proximal Ring Voltage Threshold</measure>
    <time_frame>Three months</time_frame>
    <description>Subject's proximal ring electrode voltage threshold was collected at the three months visit. The Model 4396 was considered effective if the mean voltage threshold was less than 3.0 Volts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects Successfully Implanted With Model 4396 Lead</measure>
    <time_frame>During implant procedure.</time_frame>
    <description>A successful implant occurs when the Model 4396 lead is implanted in a left ventricular vein and functions appropriately. A Model 4396 implant attempt was defined as any time when a Model 4396 lead was introduced into the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Successfully Implanted With Any Transvenous LV Lead After Cannulation</measure>
    <time_frame>During implant procedure.</time_frame>
    <description>A successful implant after cannulation occurs when the coronary sinus (CS) is successfully cannulated and a left ventricular lead (any transvenous LV lead) is implanted in a left ventricular vein and functions appropriately. An implant attempt of any transvenous LV lead was defined as any time when a transvenous LV lead was introduced into the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Successfully Implanted With Any Transvenous LV Lead</measure>
    <time_frame>During implant procedure.</time_frame>
    <description>A successful implant occurs when any transvenous LV lead is implanted in a left ventricular vein functions appropriately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Successfully Implanted With Any Medtronic Attain Family LV Lead</measure>
    <time_frame>During implant procedure.</time_frame>
    <description>A successful implant occurs when any Medtronic Attain Family LV Lead is implanted in a left ventricular vein and functions appropriately. The Attain Family leads include the following models: 4193, 4194, 4195, 4196, and 4396.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cannulation Time</measure>
    <time_frame>During implant procedure.</time_frame>
    <description>Cannulation time was defined as the time from insertion of the first coronary sinus (CS) cannulation catheter to the first successful CS cannulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy Time</measure>
    <time_frame>During implant procedure.</time_frame>
    <description>The total time the fluoroscope was imaging (not including biplane fluoroscopy time).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model 4396 Lead Placement Time</measure>
    <time_frame>During implant procedure.</time_frame>
    <description>Model 4396 lead placement time was defined as the time from insertion of the successfully implanted lead to the time when it was placed in the first acceptable pacing location.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Operation Time</measure>
    <time_frame>During implant procedure.</time_frame>
    <description>Total operation time was defined as time from initial incision to final closure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Lead Handling Characteristics Reported as Acceptable</measure>
    <time_frame>During implant procedure.</time_frame>
    <description>Implant lead handling characteristics were qualitatively assessed through physician feedback on the Implant Case Report Form (CRF). Physicians were asked for their overall assessment of the lead and results were categorized as acceptable or unacceptable. The number of acceptable responses are summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Bipolar Voltage Threshold</measure>
    <time_frame>1 month</time_frame>
    <description>Subjects' voltage threshold in the bipolar configuration was collected at the one month visit. The Model 4396 was considered effective if the mean voltage threshold (at 0.5 milliseconds [ms]) is less than or equal to 4.0 Volts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Model 4396 Electrical Performance- Tip Electrode: Voltage Threshold</measure>
    <time_frame>6 month</time_frame>
    <description>Tip electrode voltage threshold at 0.5 ms was collected at implant, pre-hospital discharge and all scheduled follow-up visits. Voltage threshold values at the 6 month visit are summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Model 4396 Electrical Performance- Tip Electrode: Pacing Impedance</measure>
    <time_frame>6 month</time_frame>
    <description>Subjects' tip electrode pacing impedance (a measure of electrical resistance) was measured at implant, pre-hospital discharge and all scheduled follow-up visits. Pacing impedance at the 6 month visit is presented here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Model 4396 Electrical Performance- Tip Electrode: Sensing</measure>
    <time_frame>6 month</time_frame>
    <description>Tip electrode sensing, measured by R-wave amplitude, for the Model 4396 was collected at implant, pre-hospital discharge and all scheduled follow-up visits. Measurements at the 6 month visit are presented here. Sensing is the minimum energy produced by the left ventricle of the heart that the device can sense.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Model 4396 Electrical Performance- Ring Electrode: Voltage Threshold</measure>
    <time_frame>6 month</time_frame>
    <description>Ring electrode voltage threshold at 0.5 ms was collected at implant, pre-hospital discharge and all scheduled follow-up visits. Voltage threshold at the 6 month visit is presented here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Model 4396 Electrical Performance- Ring Electrode: Pacing Impedance</measure>
    <time_frame>6 month</time_frame>
    <description>Subjects' ring electrode pacing impedance was measured at implant, pre-hospital discharge and all scheduled follow-up visits. Pacing impedance at the 6 month visit is presented here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Model 4396 Electrical Performance- Ring Electrode: Sensing</measure>
    <time_frame>During implant procedure.</time_frame>
    <description>Ring electrode sensing, measured by R-wave amplitude, for the Model 4396 was collected only at the implant procedure because the devices allowed in this study are not programmable to collect sensing measurements using the ring electrode. The analyzer was used to collect measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Model 4396 Electrical Performance- Bipolar Configuration: Voltage Threshold</measure>
    <time_frame>6 month</time_frame>
    <description>Bipolar voltage threshold at 0.5 ms was collected at implant, pre-hospital discharge and all scheduled follow-up visits. Voltage threshold at the 6 month visit is reported here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Model 4396 Electrical Performance- Bipolar Configuration: Pacing Impedance</measure>
    <time_frame>6 month</time_frame>
    <description>Subjects' bipolar pacing impedance was measured at implant, pre-hospital discharge and all scheduled follow-up visits. Pacing impedance at the 6 month visit is presented here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Model 4396 Electrical Performance- Bipolar Configuration: Sensing</measure>
    <time_frame>6 month</time_frame>
    <description>Bipolar sensing, measured by R-wave amplitude, for the Model 4396 was collected at implant, pre-hospital discharge and all scheduled follow-up visits. Measurements at the 6 month visit are presented here.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Model 4396 LV Lead</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-randomized study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pacing Lead</intervention_name>
    <description>implant and follow-up of study device</description>
    <arm_group_label>Model 4396 LV Lead</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CRT/Cardiac Resynchronization Therapy-Defibrillator (CRT-D) indications, New York
             Heart Association (NYHA) III and IV, indicated for implantable cardiac defibrillator
             (ICD) if CRT-D is implanted, patient consent, geographically stable

        Exclusion Criteria:

          -  LV lead implant attempt in last 30 days, unstable angina or acute myocardial
             infarction (MI) in past 30 days, coronary artery bypass graft (CABG) or percutaneous
             transluminal coronary angioplasty (PTCA) in past 3 months, contraindicated for
             transvenous pacing, heart transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek Exner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Foothills Hospital (University of Calgary)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Gras, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nouvelles Cliniques Nantaises</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bendigo</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Italy</country>
    <country>Saudi Arabia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2009</study_first_submitted>
  <study_first_submitted_qc>February 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2009</study_first_posted>
  <results_first_submitted>August 25, 2011</results_first_submitted>
  <results_first_submitted_qc>October 27, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 5, 2011</results_first_posted>
  <disposition_first_submitted>May 27, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>May 27, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 2, 2010</disposition_first_posted>
  <last_update_submitted>February 1, 2012</last_update_submitted>
  <last_update_submitted_qc>February 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>cardiac pacing</keyword>
  <keyword>cardiac resynchronization therapy</keyword>
  <keyword>left ventricular lead</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Model 4396 LV Lead</title>
          <description>Subjects successfully implanted with a Model 4396 LV lead.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Implant Attempted</title>
              <participants_list>
                <participants group_id="P1" count="193"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Model 4396 Lead Attempted</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subjects did not receive a 4396 lead</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Model 4396 lead not attempted</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Implant not attempted</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Model 4396 LV Lead</title>
          <description>Subjects underwent Model 4396 left ventricular lead implant attempt</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="193"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>All subjects who underwent an implant attempt (193) were included in the study population analysis.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>All subjects who underwent an implant attempt (193) were included in the study population analysis.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.6" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>All subjects who underwent an implant attempt (193) were included in the study population analysis.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>All subjects who underwent an implant attempt (193) were included in the study population analysis.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Saudi Arabia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association</title>
          <description>All subjects who underwent an implant attempt (193) were included in the study population analysis</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <description>All subjects who underwent an implant attempt (193) were included in the study population.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White/Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject chose not to provide information</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intrinsic QRS Width</title>
          <description>All subjects who underwent an implant attempt (193) were included in the study population analysis.</description>
          <units>Milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154.1" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricular Ejection Fraction (LVEF)</title>
          <description>All subjects who underwent an implant attempt (193) were included in the study population analysis. Note, one subject did not have a LVEF within 365 days of baseline and a study deviation was reported for not meeting inclusion/exclusion criteria.</description>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.7" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety (Subjects Without a Model 4396 Lead Related Complication)</title>
        <description>A subject who was free of a Model 4396 lead related complication by the one month visit. All adverse events (AE) in the time frame were recorded at the subject's center and assessed by a centralized Adverse Event Advisory Committee (AEAC). The AEAC determined whether an AE was a complication and whether the event was related to the Model 4396 lead. A complication is an AE that results in death, termination of significant device function or invasive intervention (any therapy that penetrates the skin including administration of intramuscular (IM) and parenteral (IV) fluids).</description>
        <time_frame>One month</time_frame>
        <population>Subjects who underwent a Model 4396 left ventricular (LV) lead implant attempt and had a 1 month follow-up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Model 4396 LV Lead</title>
            <description>Subjects who underwent a Model 4396 left ventricular lead implant attempt</description>
          </group>
        </group_list>
        <measure>
          <title>Safety (Subjects Without a Model 4396 Lead Related Complication)</title>
          <description>A subject who was free of a Model 4396 lead related complication by the one month visit. All adverse events (AE) in the time frame were recorded at the subject's center and assessed by a centralized Adverse Event Advisory Committee (AEAC). The AEAC determined whether an AE was a complication and whether the event was related to the Model 4396 lead. A complication is an AE that results in death, termination of significant device function or invasive intervention (any therapy that penetrates the skin including administration of intramuscular (IM) and parenteral (IV) fluids).</description>
          <population>Subjects who underwent a Model 4396 left ventricular (LV) lead implant attempt and had a 1 month follow-up visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155" lower_limit="90.6" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>One sample proportion</param_type>
            <param_value>.951</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>.906</ci_lower_limit>
            <estimate_desc>The Model 4396 lead will be considered safe if the proportion of subjects free of Model 4396 lead-related complications at one month post-implant is greater than 80% (i.e. the one sided 95% lower confidence bound must be at least 80%).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy: Distal Tip Electrode Voltage Threshold</title>
        <description>Subjects' distal tip electrode voltage threshold was collected at the one month visit. The Model 4396 was considered effective if the mean voltage threshold was less than 3.0 Volts. Voltage threshold was collected using LV tip to Right Ventricular (RV) coil configuration at 0.5 milliseconds [ms]. Voltage threshold is the minimum energy required from the device to consistently pace the ventricle.</description>
        <time_frame>One month</time_frame>
        <population>Only subjects with pacing thresholds captured at 0.5 ms were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Model 4396 LV Lead</title>
            <description>Subjects with tip electrode capture at 0.5ms at 1-month.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Distal Tip Electrode Voltage Threshold</title>
          <description>Subjects' distal tip electrode voltage threshold was collected at the one month visit. The Model 4396 was considered effective if the mean voltage threshold was less than 3.0 Volts. Voltage threshold was collected using LV tip to Right Ventricular (RV) coil configuration at 0.5 milliseconds [ms]. Voltage threshold is the minimum energy required from the device to consistently pace the ventricle.</description>
          <population>Only subjects with pacing thresholds captured at 0.5 ms were included in the analysis.</population>
          <units>Volts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>One sample mean</param_type>
            <param_value>1.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy: Proximal Ring Voltage Threshold</title>
        <description>Subject's proximal ring electrode voltage threshold was collected at the three months visit. The Model 4396 was considered effective if the mean voltage threshold was less than 3.0 Volts.</description>
        <time_frame>Three months</time_frame>
        <population>Subjects with ring electrode threshold captured at 0.5 ms at 3-month</population>
        <group_list>
          <group group_id="O1">
            <title>Model 4396 LV Lead</title>
            <description>Subjects with ring electrode threshold captured at 0.5ms at 3-month.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Proximal Ring Voltage Threshold</title>
          <description>Subject's proximal ring electrode voltage threshold was collected at the three months visit. The Model 4396 was considered effective if the mean voltage threshold was less than 3.0 Volts.</description>
          <population>Subjects with ring electrode threshold captured at 0.5 ms at 3-month</population>
          <units>Volts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>One sample mean</param_type>
            <param_value>2.3</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.0</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Successfully Implanted With Model 4396 Lead</title>
        <description>A successful implant occurs when the Model 4396 lead is implanted in a left ventricular vein and functions appropriately. A Model 4396 implant attempt was defined as any time when a Model 4396 lead was introduced into the body.</description>
        <time_frame>During implant procedure.</time_frame>
        <population>Subjects who underwent Model 4396 LV implant attempt.</population>
        <group_list>
          <group group_id="O1">
            <title>Model 4396 LV Lead</title>
            <description>Subjects successfully implanted with a Model 4396 LV lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Successfully Implanted With Model 4396 Lead</title>
          <description>A successful implant occurs when the Model 4396 lead is implanted in a left ventricular vein and functions appropriately. A Model 4396 implant attempt was defined as any time when a Model 4396 lead was introduced into the body.</description>
          <population>Subjects who underwent Model 4396 LV implant attempt.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>One sample proportion</param_type>
            <param_value>.927</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.887</ci_lower_limit>
            <ci_upper_limit>.967</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Successfully Implanted With Any Transvenous LV Lead After Cannulation</title>
        <description>A successful implant after cannulation occurs when the coronary sinus (CS) is successfully cannulated and a left ventricular lead (any transvenous LV lead) is implanted in a left ventricular vein and functions appropriately. An implant attempt of any transvenous LV lead was defined as any time when a transvenous LV lead was introduced into the body.</description>
        <time_frame>During implant procedure.</time_frame>
        <population>Subjects with successful CS cannulation after an implant attempt.</population>
        <group_list>
          <group group_id="O1">
            <title>Any Transvenous LV Lead</title>
            <description>Subjects who underwent an implant attempt with successful CS cannulation.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Successfully Implanted With Any Transvenous LV Lead After Cannulation</title>
          <description>A successful implant after cannulation occurs when the coronary sinus (CS) is successfully cannulated and a left ventricular lead (any transvenous LV lead) is implanted in a left ventricular vein and functions appropriately. An implant attempt of any transvenous LV lead was defined as any time when a transvenous LV lead was introduced into the body.</description>
          <population>Subjects with successful CS cannulation after an implant attempt.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>One sample proportion</param_type>
            <param_value>.969</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.944</ci_lower_limit>
            <ci_upper_limit>.993</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Successfully Implanted With Any Transvenous LV Lead</title>
        <description>A successful implant occurs when any transvenous LV lead is implanted in a left ventricular vein functions appropriately.</description>
        <time_frame>During implant procedure.</time_frame>
        <population>Subjects who underwent an implant attempt.</population>
        <group_list>
          <group group_id="O1">
            <title>Any Transvenous LV Lead</title>
            <description>Subjects who underwent an implant attempt.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Successfully Implanted With Any Transvenous LV Lead</title>
          <description>A successful implant occurs when any transvenous LV lead is implanted in a left ventricular vein functions appropriately.</description>
          <population>Subjects who underwent an implant attempt.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>One sample proportion</param_type>
            <param_value>.959</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.930</ci_lower_limit>
            <ci_upper_limit>.987</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Successfully Implanted With Any Medtronic Attain Family LV Lead</title>
        <description>A successful implant occurs when any Medtronic Attain Family LV Lead is implanted in a left ventricular vein and functions appropriately. The Attain Family leads include the following models: 4193, 4194, 4195, 4196, and 4396.</description>
        <time_frame>During implant procedure.</time_frame>
        <population>Subjects who underwent an implant attempt.</population>
        <group_list>
          <group group_id="O1">
            <title>Any Medtronic LV Lead (Attain Family Lead)</title>
            <description>Subjects who underwent an implant attempt.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Successfully Implanted With Any Medtronic Attain Family LV Lead</title>
          <description>A successful implant occurs when any Medtronic Attain Family LV Lead is implanted in a left ventricular vein and functions appropriately. The Attain Family leads include the following models: 4193, 4194, 4195, 4196, and 4396.</description>
          <population>Subjects who underwent an implant attempt.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>One sample proportion</param_type>
            <param_value>.948</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.917</ci_lower_limit>
            <ci_upper_limit>.979</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cannulation Time</title>
        <description>Cannulation time was defined as the time from insertion of the first coronary sinus (CS) cannulation catheter to the first successful CS cannulation.</description>
        <time_frame>During implant procedure.</time_frame>
        <population>Subjects successfully implanted with a Model 4396 lead.</population>
        <group_list>
          <group group_id="O1">
            <title>Model 4396 LV Lead</title>
            <description>Subjects successfully implanted with a Model 4396 LV lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Cannulation Time</title>
          <description>Cannulation time was defined as the time from insertion of the first coronary sinus (CS) cannulation catheter to the first successful CS cannulation.</description>
          <population>Subjects successfully implanted with a Model 4396 lead.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluoroscopy Time</title>
        <description>The total time the fluoroscope was imaging (not including biplane fluoroscopy time).</description>
        <time_frame>During implant procedure.</time_frame>
        <population>Subjects successfully implanted with a Model 4396 lead. Note that one subject's standard fluoroscopy time was not collected and a study deviation was reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Model 4396 LV Lead</title>
            <description>Subjects successfully implanted with a Model 4396 LV lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Fluoroscopy Time</title>
          <description>The total time the fluoroscope was imaging (not including biplane fluoroscopy time).</description>
          <population>Subjects successfully implanted with a Model 4396 lead. Note that one subject's standard fluoroscopy time was not collected and a study deviation was reported.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Model 4396 Lead Placement Time</title>
        <description>Model 4396 lead placement time was defined as the time from insertion of the successfully implanted lead to the time when it was placed in the first acceptable pacing location.</description>
        <time_frame>During implant procedure.</time_frame>
        <population>Subjects successfully implanted with a Model 4396 lead. Note that one subject's LV Lead placement time was permanently missing and a study deviation was reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Model 4396 LV Lead</title>
            <description>Subjects successfully implanted with a Model 4396 LV lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Model 4396 Lead Placement Time</title>
          <description>Model 4396 lead placement time was defined as the time from insertion of the successfully implanted lead to the time when it was placed in the first acceptable pacing location.</description>
          <population>Subjects successfully implanted with a Model 4396 lead. Note that one subject's LV Lead placement time was permanently missing and a study deviation was reported.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Operation Time</title>
        <description>Total operation time was defined as time from initial incision to final closure.</description>
        <time_frame>During implant procedure.</time_frame>
        <population>Subjects successfully implanted with a Model 4396 lead.</population>
        <group_list>
          <group group_id="O1">
            <title>Model 4396 LV Lead</title>
            <description>Subjects successfully implanted with a Model 4396 LV lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Operation Time</title>
          <description>Total operation time was defined as time from initial incision to final closure.</description>
          <population>Subjects successfully implanted with a Model 4396 lead.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" spread="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Lead Handling Characteristics Reported as Acceptable</title>
        <description>Implant lead handling characteristics were qualitatively assessed through physician feedback on the Implant Case Report Form (CRF). Physicians were asked for their overall assessment of the lead and results were categorized as acceptable or unacceptable. The number of acceptable responses are summarized.</description>
        <time_frame>During implant procedure.</time_frame>
        <population>Subjects who underwent a Model 4396 left ventricular lead implant attempt.</population>
        <group_list>
          <group group_id="O1">
            <title>Model 4396 LV Lead</title>
            <description>Model 4396 lead implant attempts.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Lead Handling Characteristics Reported as Acceptable</title>
          <description>Implant lead handling characteristics were qualitatively assessed through physician feedback on the Implant Case Report Form (CRF). Physicians were asked for their overall assessment of the lead and results were categorized as acceptable or unacceptable. The number of acceptable responses are summarized.</description>
          <population>Subjects who underwent a Model 4396 left ventricular lead implant attempt.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Bipolar Voltage Threshold</title>
        <description>Subjects' voltage threshold in the bipolar configuration was collected at the one month visit. The Model 4396 was considered effective if the mean voltage threshold (at 0.5 milliseconds [ms]) is less than or equal to 4.0 Volts.</description>
        <time_frame>1 month</time_frame>
        <population>Subjects that were implanted with a Model 4396 lead and completed the 1 month visit</population>
        <group_list>
          <group group_id="O1">
            <title>Model 4396 LV Lead</title>
            <description>Subjects successfully implanted with a Model 4396 LV lead and completed 1 month visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Bipolar Voltage Threshold</title>
          <description>Subjects' voltage threshold in the bipolar configuration was collected at the one month visit. The Model 4396 was considered effective if the mean voltage threshold (at 0.5 milliseconds [ms]) is less than or equal to 4.0 Volts.</description>
          <population>Subjects that were implanted with a Model 4396 lead and completed the 1 month visit</population>
          <units>Volts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>One sample mean</param_type>
            <param_value>2.4</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Model 4396 Electrical Performance- Tip Electrode: Voltage Threshold</title>
        <description>Tip electrode voltage threshold at 0.5 ms was collected at implant, pre-hospital discharge and all scheduled follow-up visits. Voltage threshold values at the 6 month visit are summarized.</description>
        <time_frame>6 month</time_frame>
        <population>Subjects with tip electrode threshold captured at 0.5 ms at 6 month</population>
        <group_list>
          <group group_id="O1">
            <title>Model 4396 LV Lead</title>
            <description>Subjects with tip electrode threshold captured at 0.5ms at 6 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Model 4396 Electrical Performance- Tip Electrode: Voltage Threshold</title>
          <description>Tip electrode voltage threshold at 0.5 ms was collected at implant, pre-hospital discharge and all scheduled follow-up visits. Voltage threshold values at the 6 month visit are summarized.</description>
          <population>Subjects with tip electrode threshold captured at 0.5 ms at 6 month</population>
          <units>Volts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Model 4396 Electrical Performance- Tip Electrode: Pacing Impedance</title>
        <description>Subjects' tip electrode pacing impedance (a measure of electrical resistance) was measured at implant, pre-hospital discharge and all scheduled follow-up visits. Pacing impedance at the 6 month visit is presented here.</description>
        <time_frame>6 month</time_frame>
        <population>Subjects with tip electrode pacing impedance at 6 month</population>
        <group_list>
          <group group_id="O1">
            <title>Model 4396 LV Lead</title>
            <description>Subjects with tip electrode pacing impedance at 6 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Model 4396 Electrical Performance- Tip Electrode: Pacing Impedance</title>
          <description>Subjects' tip electrode pacing impedance (a measure of electrical resistance) was measured at implant, pre-hospital discharge and all scheduled follow-up visits. Pacing impedance at the 6 month visit is presented here.</description>
          <population>Subjects with tip electrode pacing impedance at 6 month</population>
          <units>Ohms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="571.2" spread="155.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Model 4396 Electrical Performance- Tip Electrode: Sensing</title>
        <description>Tip electrode sensing, measured by R-wave amplitude, for the Model 4396 was collected at implant, pre-hospital discharge and all scheduled follow-up visits. Measurements at the 6 month visit are presented here. Sensing is the minimum energy produced by the left ventricle of the heart that the device can sense.</description>
        <time_frame>6 month</time_frame>
        <population>Subjects with tip electrode R-wave amplitude at 6 month</population>
        <group_list>
          <group group_id="O1">
            <title>Model 4396 LV Lead</title>
            <description>Subjects with ring electrode R-wave amplitude at 6 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Model 4396 Electrical Performance- Tip Electrode: Sensing</title>
          <description>Tip electrode sensing, measured by R-wave amplitude, for the Model 4396 was collected at implant, pre-hospital discharge and all scheduled follow-up visits. Measurements at the 6 month visit are presented here. Sensing is the minimum energy produced by the left ventricle of the heart that the device can sense.</description>
          <population>Subjects with tip electrode R-wave amplitude at 6 month</population>
          <units>mV</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Model 4396 Electrical Performance- Ring Electrode: Voltage Threshold</title>
        <description>Ring electrode voltage threshold at 0.5 ms was collected at implant, pre-hospital discharge and all scheduled follow-up visits. Voltage threshold at the 6 month visit is presented here.</description>
        <time_frame>6 month</time_frame>
        <population>Subjects with ring electrode threshold captured at 0.5 ms at 6 month</population>
        <group_list>
          <group group_id="O1">
            <title>Model 4396 LV Lead</title>
            <description>Subjects with ring electrode threshold captured at 0.5 ms at 6 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Model 4396 Electrical Performance- Ring Electrode: Voltage Threshold</title>
          <description>Ring electrode voltage threshold at 0.5 ms was collected at implant, pre-hospital discharge and all scheduled follow-up visits. Voltage threshold at the 6 month visit is presented here.</description>
          <population>Subjects with ring electrode threshold captured at 0.5 ms at 6 month</population>
          <units>Volts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Model 4396 Electrical Performance- Ring Electrode: Pacing Impedance</title>
        <description>Subjects' ring electrode pacing impedance was measured at implant, pre-hospital discharge and all scheduled follow-up visits. Pacing impedance at the 6 month visit is presented here.</description>
        <time_frame>6 month</time_frame>
        <population>Subjects with ring electrode pacing impedance at 6 month</population>
        <group_list>
          <group group_id="O1">
            <title>Model 4396 LV Lead</title>
            <description>Subjects with ring electrode pacing impedance at 6 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Model 4396 Electrical Performance- Ring Electrode: Pacing Impedance</title>
          <description>Subjects' ring electrode pacing impedance was measured at implant, pre-hospital discharge and all scheduled follow-up visits. Pacing impedance at the 6 month visit is presented here.</description>
          <population>Subjects with ring electrode pacing impedance at 6 month</population>
          <units>Ohms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="544.8" spread="149.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Model 4396 Electrical Performance- Ring Electrode: Sensing</title>
        <description>Ring electrode sensing, measured by R-wave amplitude, for the Model 4396 was collected only at the implant procedure because the devices allowed in this study are not programmable to collect sensing measurements using the ring electrode. The analyzer was used to collect measurements.</description>
        <time_frame>During implant procedure.</time_frame>
        <population>Subjects with ring electrode R-wave amplitude at implant</population>
        <group_list>
          <group group_id="O1">
            <title>Model 4396 LV Lead</title>
            <description>Subjects with ring electrode R-wave amplitude at implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Model 4396 Electrical Performance- Ring Electrode: Sensing</title>
          <description>Ring electrode sensing, measured by R-wave amplitude, for the Model 4396 was collected only at the implant procedure because the devices allowed in this study are not programmable to collect sensing measurements using the ring electrode. The analyzer was used to collect measurements.</description>
          <population>Subjects with ring electrode R-wave amplitude at implant</population>
          <units>mV</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Model 4396 Electrical Performance- Bipolar Configuration: Voltage Threshold</title>
        <description>Bipolar voltage threshold at 0.5 ms was collected at implant, pre-hospital discharge and all scheduled follow-up visits. Voltage threshold at the 6 month visit is reported here.</description>
        <time_frame>6 month</time_frame>
        <population>Subjects with bipolar configuration threshold captured at 0.5 ms at 6 month</population>
        <group_list>
          <group group_id="O1">
            <title>Model 4396 LV Lead</title>
            <description>Subjects with bipolar configuration threshold captured at 0.5ms at 6 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Model 4396 Electrical Performance- Bipolar Configuration: Voltage Threshold</title>
          <description>Bipolar voltage threshold at 0.5 ms was collected at implant, pre-hospital discharge and all scheduled follow-up visits. Voltage threshold at the 6 month visit is reported here.</description>
          <population>Subjects with bipolar configuration threshold captured at 0.5 ms at 6 month</population>
          <units>Volts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Model 4396 Electrical Performance- Bipolar Configuration: Pacing Impedance</title>
        <description>Subjects' bipolar pacing impedance was measured at implant, pre-hospital discharge and all scheduled follow-up visits. Pacing impedance at the 6 month visit is presented here.</description>
        <time_frame>6 month</time_frame>
        <population>Subjects with bipolar configuration pacing impedance at 6 month</population>
        <group_list>
          <group group_id="O1">
            <title>Model 4396 LV Lead</title>
            <description>Subjects with bipolar configuration pacing impedance at 6 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Model 4396 Electrical Performance- Bipolar Configuration: Pacing Impedance</title>
          <description>Subjects' bipolar pacing impedance was measured at implant, pre-hospital discharge and all scheduled follow-up visits. Pacing impedance at the 6 month visit is presented here.</description>
          <population>Subjects with bipolar configuration pacing impedance at 6 month</population>
          <units>Ohms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="967.1" spread="239.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Model 4396 Electrical Performance- Bipolar Configuration: Sensing</title>
        <description>Bipolar sensing, measured by R-wave amplitude, for the Model 4396 was collected at implant, pre-hospital discharge and all scheduled follow-up visits. Measurements at the 6 month visit are presented here.</description>
        <time_frame>6 month</time_frame>
        <population>Subjects with bipolar configuration electrode R-wave amplitude at 6 month.</population>
        <group_list>
          <group group_id="O1">
            <title>Model 4396 LV Lead</title>
            <description>Subjects with bipolar configuration R-wave amplitude at 6 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Model 4396 Electrical Performance- Bipolar Configuration: Sensing</title>
          <description>Bipolar sensing, measured by R-wave amplitude, for the Model 4396 was collected at implant, pre-hospital discharge and all scheduled follow-up visits. Measurements at the 6 month visit are presented here.</description>
          <population>Subjects with bipolar configuration electrode R-wave amplitude at 6 month.</population>
          <units>mV</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subject enrollment-exit</time_frame>
      <desc>Reported Adverse Events (AE) were documented on study case report forms as they occurred. Serious AE: AE that led to death, or led to worse health that resulted in: life-threatening illness or injury; a permanent impairment of a body function; hosp.; medical intervention or surgery to prevent permanent impairment to body structure or body function</desc>
      <group_list>
        <group group_id="E1">
          <title>Model 4396 LV Lead</title>
          <description>Subjects successfully implanted with a Model 4396 LV lead.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm of aortic arch</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Asystole</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation with rapid ventricular response</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Coronary artery disease aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Decompensated heart failure</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Non ST segment elevation myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Triple vessel disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>GI bleed</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Small bowel obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Chest tenderness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Fever of unknown origin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Implant site hematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Multiple organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Foot infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Implant site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Device lead issue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Elevated pacing threshold</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Inadequate lead connection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Inappropriate phrenic nerve stimulation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Laceration of head</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Lead dislodgement</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Loss of capture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Twiddler's syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Insulin hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Loss of control of diabetes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Degenerative joint disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Prostatic hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Herniated disc</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Intracerebral hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Middle cerebral artery stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Near syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack (TIA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholic withdrawal symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Effusion pleural</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Embolism pulmonary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep venous thrombosis arm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Embolus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Femoral artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Uncontrolled hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Inappropriate phrenic nerve stimulation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Inappropriate stimulation of diaphragm</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>4396 Clinical Research Specialist</name_or_title>
      <organization>Medtronic, Inc</organization>
      <phone>800-328-2518 ext 62808</phone>
      <email>medtronicCRMtrials@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

